PROCEPT BioRobotics Q3 2025: 93% Revenue Growth in Robotic Urology
PROCEPT BioRobotics Corporation unveiled its third-quarter 2025 financial results on November 4, showing strong growth in its robotic urology solutions. The company, founded in 2009 and headquartered in Redwood City, California, specializes in innovative medical devices for treating benign prostatic hyperplasia (BPH), a common condition affecting millions of men worldwide.
At the heart of their success is the AquaBeam Robotic System, which delivers Aquablation therapy—a precise, heat-free waterjet treatment that removes excess prostate tissue while preserving vital functions. This FDA-approved technology uses real-time imaging and a personalized treatment plan to minimize side effects like incontinence or sexual dysfunction, setting it apart from traditional surgical methods.
Revenue for the quarter surged 93 percent year-over-year to $31.9 million, driven by increased adoption in hospitals across the U.S. and Europe. Procedure volume climbed 80 percent, reflecting surgeon confidence in the system's accuracy and patient outcomes. PROCEPT's CEO, Raman D. Patil, highlighted the expansion of their commercial team and new partnerships as key factors fueling this momentum.
With over 1,000 systems installed globally and a growing body of clinical data, PROCEPT is positioning itself as a leader in robotic-assisted urology. Investors responded positively, with shares rising in after-hours trading. As minimally invasive treatments gain traction, this milestone underscores the transformative potential of robotics in everyday medicine.